Novocure (NVCR) said Monday that the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial of Tumor Treating Fields together with paclitaxel in patients with platinum-resistant ovarian cancer did not meet its primary endpoint of overall survival at the final analysis.
from RTT - Before the Bell https://ift.tt/ZCFqU2k
via IFTTT
No comments:
Post a Comment